Current Gastroenterology Reports

, Volume 11, Issue 6, pp 509–517

Managing the risks of IBD therapy

Authors

    • University of Calgary
  • Shanika de Silva
  • Gilaad G. Kaplan
  • Shane M. Devlin
  • Subrata Ghosh
  • Remo Panaccione
Article

DOI: 10.1007/s11894-009-0077-4

Cite this article as:
Seow, C.H., de Silva, S., Kaplan, G.G. et al. Curr Gastroenterol Rep (2009) 11: 509. doi:10.1007/s11894-009-0077-4

Abstract

Successful management of the patient with inflammatory bowel disease (IBD) involves not only the induction and maintenance of remission, but also the optimization of the benefit-to-risk equation to achieve the greatest gain in quality of life. These risks range from intolerance to prescribed medications to potentially life-threatening sequelae (eg, sepsis) of immune suppression. A proper awareness of risk on the part of the physician and education of the patient can lead to early detection and institution of an appropriate management plan, including risk management and, optimally, primary prevention (eg, prophylactic vaccination). One should take the opportunity regularly to reassess the utility and efficacy of existing therapy, with the provision of ineffective therapies mandating urgent review. Overall, optimal management of the patient with IBD requires open dialogue between clinician and patient so that both are cognizant of the goals, benefits, and potential risks of therapy.

Copyright information

© Springer Science+Business Media, LLC 2009